Nystatin prophylaxis and treatment in severely immunodepressed patients
- PMID: 12076436
- DOI: 10.1002/14651858.CD002033
Nystatin prophylaxis and treatment in severely immunodepressed patients
Update in
-
Nystatin prophylaxis and treatment in severely immunodepressed patients.Cochrane Database Syst Rev. 2002;(4):CD002033. doi: 10.1002/14651858.CD002033. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2014 Sep 04;(9):CD002033. doi: 10.1002/14651858.CD002033.pub2. PMID: 12519566 Updated. Review.
Abstract
Background: Nystatin is sometimes used prophylactically in patients with severe immunodeficiency or in the treatment of fungal infection in such patients, although the effect seems to be equivocal.
Objectives: To study whether nystatin decreases morbidity and mortality when given prophylactically or therapeutically to patients with severe immunodeficiency.
Search strategy: MEDLINE and The Cochrane Library using a comprehensive search strategy, date of last search November 2001. Contacted industry and scanned reference lists.
Selection criteria: Randomised trials comparing nystatin with placebo, an untreated control group, fluconazole or amphotericin B.
Data collection and analysis: Data on mortality, invasive fungal infection and colonisation were extracted by both authors independently. The outcomes were weighted by the inverse variance. A random effects model was used unless p>0.10 for the test of heterogeneity.
Main results: We included 12 trials (1,464 patients). The drugs were given prophylactically in ten trials and as treatment in two. Seven trials were in acute leukaemia, two in cancer, one in liver transplant patients, one in critically ill surgical and trauma patients, and one in AIDS patients. Nystatin had been compared with placebo in three trials and with fluconazole in nine; the dose varied from 1.5 MIE to 72 MIE daily. The effect of nystatin was similar to that of placebo on fungal colonisation (relative risk 0.85, 95% confidence interval 0.65 to 1.13). There was no statistically significant difference between fluconazole and nystatin on mortality (relative risk 0.76, 0.49 to 1.18) whereas fluconazole was more effective in preventing invasive fungal infection (relative risk 0.37, 0.15 to 0.91) and colonisation (relative risk 0.49, 0.34 to 0.70). The results were very similar if the three studies which were not performed in cancer patients were excluded.
Reviewer's conclusions: Nystatin cannot be recommended for prophylaxis or treatment of Candida infections in immunodepressed patients.
Update of
-
Nystatin prophylaxis and treatment in severely immunodepressed patients.Cochrane Database Syst Rev. 2000;(2):CD002033. doi: 10.1002/14651858.CD002033. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(2):CD002033. doi: 10.1002/14651858.CD002033. PMID: 10796846 Updated. Review.
Similar articles
-
Nystatin prophylaxis and treatment in severely immunodepressed patients.Cochrane Database Syst Rev. 2002;(4):CD002033. doi: 10.1002/14651858.CD002033. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2014 Sep 04;(9):CD002033. doi: 10.1002/14651858.CD002033.pub2. PMID: 12519566 Updated. Review.
-
Nystatin prophylaxis and treatment in severely immunodepressed patients.Cochrane Database Syst Rev. 2000;(2):CD002033. doi: 10.1002/14651858.CD002033. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(2):CD002033. doi: 10.1002/14651858.CD002033. PMID: 10796846 Updated. Review.
-
Nystatin prophylaxis and treatment in severely immunodepressed patients.Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD002033. doi: 10.1002/14651858.CD002033.pub2. Cochrane Database Syst Rev. 2014. PMID: 25188770 Free PMC article. Review.
-
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004920. doi: 10.1002/14651858.CD004920.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2016 Jan 16;(1):CD004920. doi: 10.1002/14651858.CD004920.pub3. PMID: 16437504 Updated. Review.
-
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.Cochrane Database Syst Rev. 2002;(2):CD000239. doi: 10.1002/14651858.CD000239. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2014 Sep 04;(9):CD000239. doi: 10.1002/14651858.CD000239.pub2. PMID: 12076388 Updated. Review.
Cited by
-
Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.Microorganisms. 2020 Jan 22;8(2):154. doi: 10.3390/microorganisms8020154. Microorganisms. 2020. PMID: 31979032 Free PMC article. Review.
-
Oral and dental health in head and neck cancer survivors.Cancers Head Neck. 2016 Oct 19;1:14. doi: 10.1186/s41199-016-0015-8. eCollection 2016. Cancers Head Neck. 2016. PMID: 31093344 Free PMC article. Review.
-
Audit to monitor the uptake of national mouth care guidelines for children and young people being treated for cancer.Support Care Cancer. 2011 Sep;19(9):1335-41. doi: 10.1007/s00520-010-0953-3. Epub 2010 Jul 31. Support Care Cancer. 2011. PMID: 20680355
-
Antifungal management in cancer patients.Wien Med Wochenschr. 2007;157(19-20):503-10. doi: 10.1007/s10354-007-0466-y. Wien Med Wochenschr. 2007. PMID: 18030555 Review.
-
Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed?Intensive Care Med. 2005 Nov;31(11):1466-8. doi: 10.1007/s00134-005-2806-y. Epub 2005 Sep 30. Intensive Care Med. 2005. PMID: 16195906 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical